3 news items
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
PLSE
20 May 24
the Company to continue current operations as planned, statements concerning market opportunities, customer adoption and future use of the CellFX
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
PLSE
9 May 24
percutaneous procedure on a controlled and measured basis, statements concerning customer adoption and future use of the CellFX System to address a range
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
PLSE
2 May 24
, statements concerning market opportunities, customer adoption and future use of the CellFX System to address a range of conditions such as atrial
- Prev
- 1
- Next